King's College London

Research portal

Clinical outcome analysis of patients with autism spectrum disorder: analysis from the UK Medical Cannabis Registry

Research output: Contribution to journalArticlepeer-review

Standard

Clinical outcome analysis of patients with autism spectrum disorder : analysis from the UK Medical Cannabis Registry. / Erridge, Simon; Kerr-Gaffney, Jess; Holvey, Carl et al.

In: Therapeutic Advances in Psychopharmacology, Vol. 12, 20.09.2022.

Research output: Contribution to journalArticlepeer-review

Harvard

Erridge, S, Kerr-Gaffney, J, Holvey, C, Coomber, R, Barros, DAR, Bhoskar, U, Mwimba, G, Praveen, K, Symeon, C, Sachdeva-Mohan, S, Sodergren, MH & Rucker, JJ 2022, 'Clinical outcome analysis of patients with autism spectrum disorder: analysis from the UK Medical Cannabis Registry', Therapeutic Advances in Psychopharmacology, vol. 12. https://doi.org/10.1177/20451253221116240

APA

Erridge, S., Kerr-Gaffney, J., Holvey, C., Coomber, R., Barros, D. A. R., Bhoskar, U., Mwimba, G., Praveen, K., Symeon, C., Sachdeva-Mohan, S., Sodergren, M. H., & Rucker, J. J. (2022). Clinical outcome analysis of patients with autism spectrum disorder: analysis from the UK Medical Cannabis Registry. Therapeutic Advances in Psychopharmacology, 12. https://doi.org/10.1177/20451253221116240

Vancouver

Erridge S, Kerr-Gaffney J, Holvey C, Coomber R, Barros DAR, Bhoskar U et al. Clinical outcome analysis of patients with autism spectrum disorder: analysis from the UK Medical Cannabis Registry. Therapeutic Advances in Psychopharmacology. 2022 Sep 20;12. https://doi.org/10.1177/20451253221116240

Author

Erridge, Simon ; Kerr-Gaffney, Jess ; Holvey, Carl et al. / Clinical outcome analysis of patients with autism spectrum disorder : analysis from the UK Medical Cannabis Registry. In: Therapeutic Advances in Psychopharmacology. 2022 ; Vol. 12.

Bibtex Download

@article{1fb2fe2dea464f789b42b426455bbf63,
title = "Clinical outcome analysis of patients with autism spectrum disorder: analysis from the UK Medical Cannabis Registry",
abstract = "Introduction: Cannabis-based medicinal products (CBMPs) have been identified as a promising novel therapeutic for symptoms and comorbidities related to autism spectrum disorder (ASD). However, there is a paucity of clinical evidence of their efficacy and safety. This case series aims to assess changes to health-related quality of life and the incidence of adverse events in patients treated with CBMPs for associated symptoms of ASD enrolled on the UK Medical Cannabis Registry (UKMCR). Methods: Patients treated with CBMPs for ASD-related symptoms for a minimum of one month were identified from the UKMCR. Primary outcomes were changes in validated patient reported outcome measures [Generalised Anxiety Disorder-7 (GAD-7), Single-Item Sleep Quality Scale (SQS), EQ-5D-5L index values] at 1, 3, and 6 months compared to baseline. Adverse events were recorded and analysed. Statistical significance was determined by p<0.050.Results: 74 patients with ASD were included in the analysis. The mean age of participants was 32.7 (±11.6) years. There were significant improvements in general health-related quality of life and sleep as assessed by the EQ-5D-5L, SQS and GAD-7 at 1 and 3 months, with sustained changes in EQ-5D-5L and SQS at 6 months (p<0.010). There were 180 (243.2%) adverse events reported by 14 (18.9%) participants. If present, adverse events were commonly mild (n=58; 78.4%) or moderate (n=81; 109.5%), rather than severe (n=41; 55.4%).Conclusions: This study demonstrated in patients with ASD an associated improvement in general health-related quality of life, and anxiety- and sleep-specific symptoms following initiation of treatment with CBMPs. These findings, whilst promising, are limited by the confines of the study which lacks a control arm and is subject to attrition bias. Therefore, further evaluation is required with randomised controlled trials.",
author = "Simon Erridge and Jess Kerr-Gaffney and Carl Holvey and Ross Coomber and Barros, {Daniela A Riano} and Urmila Bhoskar and Gracia Mwimba and Kavita Praveen and Chris Symeon and Simmi Sachdeva-Mohan and Sodergren, {Mikael H} and Rucker, {James J}",
note = "{\textcopyright} The Author(s), 2022.",
year = "2022",
month = sep,
day = "20",
doi = "10.1177/20451253221116240",
language = "English",
volume = "12",
journal = "Therapeutic Advances in Psychopharmacology",
issn = "2045-1253",
publisher = "Sage Publications",

}

RIS (suitable for import to EndNote) Download

TY - JOUR

T1 - Clinical outcome analysis of patients with autism spectrum disorder

T2 - analysis from the UK Medical Cannabis Registry

AU - Erridge, Simon

AU - Kerr-Gaffney, Jess

AU - Holvey, Carl

AU - Coomber, Ross

AU - Barros, Daniela A Riano

AU - Bhoskar, Urmila

AU - Mwimba, Gracia

AU - Praveen, Kavita

AU - Symeon, Chris

AU - Sachdeva-Mohan, Simmi

AU - Sodergren, Mikael H

AU - Rucker, James J

N1 - © The Author(s), 2022.

PY - 2022/9/20

Y1 - 2022/9/20

N2 - Introduction: Cannabis-based medicinal products (CBMPs) have been identified as a promising novel therapeutic for symptoms and comorbidities related to autism spectrum disorder (ASD). However, there is a paucity of clinical evidence of their efficacy and safety. This case series aims to assess changes to health-related quality of life and the incidence of adverse events in patients treated with CBMPs for associated symptoms of ASD enrolled on the UK Medical Cannabis Registry (UKMCR). Methods: Patients treated with CBMPs for ASD-related symptoms for a minimum of one month were identified from the UKMCR. Primary outcomes were changes in validated patient reported outcome measures [Generalised Anxiety Disorder-7 (GAD-7), Single-Item Sleep Quality Scale (SQS), EQ-5D-5L index values] at 1, 3, and 6 months compared to baseline. Adverse events were recorded and analysed. Statistical significance was determined by p<0.050.Results: 74 patients with ASD were included in the analysis. The mean age of participants was 32.7 (±11.6) years. There were significant improvements in general health-related quality of life and sleep as assessed by the EQ-5D-5L, SQS and GAD-7 at 1 and 3 months, with sustained changes in EQ-5D-5L and SQS at 6 months (p<0.010). There were 180 (243.2%) adverse events reported by 14 (18.9%) participants. If present, adverse events were commonly mild (n=58; 78.4%) or moderate (n=81; 109.5%), rather than severe (n=41; 55.4%).Conclusions: This study demonstrated in patients with ASD an associated improvement in general health-related quality of life, and anxiety- and sleep-specific symptoms following initiation of treatment with CBMPs. These findings, whilst promising, are limited by the confines of the study which lacks a control arm and is subject to attrition bias. Therefore, further evaluation is required with randomised controlled trials.

AB - Introduction: Cannabis-based medicinal products (CBMPs) have been identified as a promising novel therapeutic for symptoms and comorbidities related to autism spectrum disorder (ASD). However, there is a paucity of clinical evidence of their efficacy and safety. This case series aims to assess changes to health-related quality of life and the incidence of adverse events in patients treated with CBMPs for associated symptoms of ASD enrolled on the UK Medical Cannabis Registry (UKMCR). Methods: Patients treated with CBMPs for ASD-related symptoms for a minimum of one month were identified from the UKMCR. Primary outcomes were changes in validated patient reported outcome measures [Generalised Anxiety Disorder-7 (GAD-7), Single-Item Sleep Quality Scale (SQS), EQ-5D-5L index values] at 1, 3, and 6 months compared to baseline. Adverse events were recorded and analysed. Statistical significance was determined by p<0.050.Results: 74 patients with ASD were included in the analysis. The mean age of participants was 32.7 (±11.6) years. There were significant improvements in general health-related quality of life and sleep as assessed by the EQ-5D-5L, SQS and GAD-7 at 1 and 3 months, with sustained changes in EQ-5D-5L and SQS at 6 months (p<0.010). There were 180 (243.2%) adverse events reported by 14 (18.9%) participants. If present, adverse events were commonly mild (n=58; 78.4%) or moderate (n=81; 109.5%), rather than severe (n=41; 55.4%).Conclusions: This study demonstrated in patients with ASD an associated improvement in general health-related quality of life, and anxiety- and sleep-specific symptoms following initiation of treatment with CBMPs. These findings, whilst promising, are limited by the confines of the study which lacks a control arm and is subject to attrition bias. Therefore, further evaluation is required with randomised controlled trials.

U2 - 10.1177/20451253221116240

DO - 10.1177/20451253221116240

M3 - Article

C2 - 36159065

VL - 12

JO - Therapeutic Advances in Psychopharmacology

JF - Therapeutic Advances in Psychopharmacology

SN - 2045-1253

ER -

View graph of relations

© 2020 King's College London | Strand | London WC2R 2LS | England | United Kingdom | Tel +44 (0)20 7836 5454